scroll to content

Client: Enterprise Ventures

Due Diligence

Deal Background

Chargepoint Technology is a Merseyside supplier of precision containment valves to pharmaceutical and chemical businesses.

These containment valves are used by almost every major pharmaceutical manufacturer, with increased use in wider markets including chemical, bio-pharmaceutical, food manufacture and consumer goods.

The business was looking to develop into emerging markets such as the Far East, as well as into other sectors including bio-pharmaceutical and food manufacturing.

How Langtons Helped

Langtons undertook Financial Due Diligence on Chargepoint Technology in relation to the Β£1.625m debt and equity investment by Enterprise Ventures.

Results

The investment in Chargepoint comprised Β£900k from the North West Fund for Mezzanine and Β£725k from the Enterprise Ventures Coalfields Fund, with both funds managed by Enterprise Ventures.

Chargepoint has since experienced significant levels of growth thanks to an increased presence in the US, Europe and Asian markets, as well as a patented new valve system catering the bio-pharmaceutical market.